- Home
- IDYA vs BSTZ Comparison
IDYA vs BSTZ Comparison
Compare IDYA & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- BSTZ
- Stock Information
- Founded
- IDYA 2015
- BSTZ 2019
- Country
- IDYA United States
- BSTZ United States
- Employees
- IDYA N/A
- BSTZ N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- BSTZ Trusts Except Educational Religious and Charitable
- Sector
- IDYA Health Care
- BSTZ Finance
- Exchange
- IDYA Nasdaq
- BSTZ Nasdaq
- Market Cap
- IDYA 1.5B
- BSTZ 1.4B
- IPO Year
- IDYA 2019
- BSTZ N/A
- Fundamental
- Price
- IDYA $21.22
- BSTZ $19.32
- Analyst Decision
- IDYA Strong Buy
- BSTZ
- Analyst Count
- IDYA 12
- BSTZ 0
- Target Price
- IDYA $54.27
- BSTZ N/A
- AVG Volume (30 Days)
- IDYA 1.5M
- BSTZ 303.2K
- Earning Date
- IDYA 05-06-2025
- BSTZ 01-01-0001
- Dividend Yield
- IDYA N/A
- BSTZ 8.31%
- EPS Growth
- IDYA N/A
- BSTZ N/A
- EPS
- IDYA N/A
- BSTZ 0.71
- Revenue
- IDYA $7,000,000.00
- BSTZ N/A
- Revenue This Year
- IDYA $68.39
- BSTZ N/A
- Revenue Next Year
- IDYA $324.54
- BSTZ N/A
- P/E Ratio
- IDYA N/A
- BSTZ $26.69
- Revenue Growth
- IDYA N/A
- BSTZ N/A
- 52 Week Low
- IDYA $13.45
- BSTZ $14.11
- 52 Week High
- IDYA $44.42
- BSTZ $19.43
- Technical
- Relative Strength Index (RSI)
- IDYA 65.40
- BSTZ 62.54
- Support Level
- IDYA $19.26
- BSTZ $18.67
- Resistance Level
- IDYA $20.46
- BSTZ $19.62
- Average True Range (ATR)
- IDYA 1.01
- BSTZ 0.31
- MACD
- IDYA 0.24
- BSTZ 0.02
- Stochastic Oscillator
- IDYA 99.55
- BSTZ 68.42
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.